Research Report
Copyright ©2014 Baishideng Publishing Group Co.
World J Clin Oncol. May 10, 2014; 5(2): 164-169
Published online May 10, 2014. doi: 10.5306/wjco.v5.i2.164
Table 1 Drugs selected in the study and their date of introduction to the Portuguese market
Drugs on the national market before 1999Market placement yrDrugs on the national market before 1999Market placement yrDrugs on the national market between 1999 and 2010Market placement yr
Aldesleukin1992Ifosfamide1979Bleomycin2001
Amifostine1995Interferon Alfa-2A1998Capecitabine2001
Anastrozole1996Intravenous vinorelbine1993Exemestane1999
Bicalutamide1998Irinotecan1997Hydroxyurea2001
Bleomycin1998Letrozole1997Imatinib2001
Carboplatin1989Megestrol1987Ketoconazole2002
Carmustine1983Melphalan1966Leuprorelin1999
Chlorambucil1966Mercaptopurine1997Liposomal Doxorubicin2000
Cisplatin1980Methotrexate1993Oral vinorelbine2001
Cyclophosphamide1960Mitomycin1984Raltitrexed2001
Cyclosporine1990Mitoxantrone1998Temozolomide1999
Cyproterone1994Octreotide1989Trastuzumab2000
Cytarabine1996Oxaliplatin1993Anagrelide2004
Dacarbazine2000Paclitaxel1997Bevacizumab2005
Dactinomycin1980Pegylated liposomal doxorubicin1996Bortezomib2004
Docetaxel1995Procarbazine1998Cetuximab2004
Doxorubicin1998Rituximab1998Erlotinib2005
Epirubicin1992Tamoxifen1984Fulvestrant2004
Etoposide1998Tegafur1985Interleukin 22005
Estramustine1982Thalidomide1961Pemetrexed2004
Fludarabine1995Topotecan1996Azacitidine2008
Fluorouracil1997Vaccine, Bacillus Calmette-Guerin1992Lapatinib2008
Flutamide1998Vinblastine1991Sorafenib2006
Gemcitabine1996Vincristine1993Sunitinib2006
Goserelin1998Temsirolimus2007
Idarubicin1995Trabectedin2008